Proteasome Inhibitor (MG-132) Treatment of mdx Mice Rescues the Expression and Membrane Localization of Dystrophin and Dystrophin-Associated Proteins
- 1 October 2003
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 163 (4) , 1663-1675
- https://doi.org/10.1016/s0002-9440(10)63523-7
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Delay of muscle degeneration and necrosis in mdx mice by calpain inhibitionMuscle & Nerve, 1999
- Caveolins, Liquid-Ordered Domains, and Signal TransductionMolecular and Cellular Biology, 1999
- Dystrophin expression in the mdx mouse restored by stem cell transplantationNature, 1999
- Phenotypic Behavior of Caveolin-3 Mutations That Cause Autosomal Dominant Limb Girdle Muscular Dystrophy (LGMD-1C)Journal of Biological Chemistry, 1999
- Increased Number of Caveolae and Caveolin-3 Overexpression in Duchenne Muscular DystrophyBiochemical and Biophysical Research Communications, 1999
- Increased caveolin‐3 levels in mdx mouse musclesFEBS Letters, 1998
- Caveolin‐3 is not an integral component of the dystrophin glycoprotein complexFEBS Letters, 1998
- Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophyNature Genetics, 1998
- Utrophin-Dystrophin-Deficient Mice as a Model for Duchenne Muscular DystrophyCell, 1997
- Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles.Journal of Clinical Investigation, 1997